Female Androgenetic Alopecia effectively treated by PRP, finds study
The eclipse system Platelet rich plasma (PRP) is found to be a safe and effective intervention in the treatment of Androgenetic Alopaecia, finds a recent trial done in the New York. The study was published in the Journal of the American Academy of Dermatology, 2020.
Androgenetic Alopecia (AGA) which is a female pattern of hair loss can cause considerable distress both emotionally and psychologically and can even decrease the quality of life. It is a non scarring type of diffuse alopecia which occurs due to genetic and hormonal factors. Apart from the regular standard treatment protocols, PRP has gained much popularity in the recent times due to its less side effects and cost affordability.
The researchers from the School of Medicine, New York conducted a prospective randomized controlled trial to determine whether PRP injections improve female AGA. 30 females diagnosed with AGA were included in the trial but 2 patients were lost to follow up. Patients received sub-dermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4 and 8. Outcome measures were changes in hair density (hair/cm2), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24.
The fey findings of the study were:
• Blinded global photographic assessment indicated that 57% of PRP patients vs. 7% of saline patients improved at week 24 from baseline (p<0.01).
• Compared to baseline, there was improvement in mean density in the PRP group vs. the placebo group at week 8 (+71.1 vs. -26.7 hairs/cm2, p<0.01) and week 24 (+105.9 vs. -52.4 hairs/cm2, p<0.01).
• Compared to baseline, there was improvement in mean caliber in the PRP group vs. the placebo group at week 8 (+0.0043 vs. -0.0034 mm, p<0.01) and week 24 (+0.0053 vs. -0.0060 mm, p<0.01).
• Adverse effects included headache, scalp tightness, swelling, redness, and post-injection bleeding.
Thus, the researchers concluded that PRP with the Eclipse system is a safe and effective intervention for female AGA.
To read more about the study, click the following link: https://doi.org/10.1016/j.jaad.2020.06.1021